Health Condition 1: M321- Systemic lupus erythematosus withorgan or system involvement
Conditions
Interventions
Intervention1: INJ METHYLPREDNISOLONE: 250mg IV OD administered for 3 days
Control Intervention1: INJ DEXAMETHASONE: 8mg IV BD administered for 3 days
Sponsors
Dr Anirudh Maslekar
Eligibility
Inclusion criteria
Inclusion criteria: 1.All hospitalised patients of Systemic Lupus Erythematosus (SLE) who have previously met or currently meet the 2012 SLICC and/or 2019 ACR criteria for SLE. 2.Moderate or severe disease activity as defined in The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults (2018) as : a. Moderate disease activity-SLEDAI-2K score in the range of 6-12. b. Severe disease activity-SLEDAI- 2K score of >12
Exclusion criteria
Exclusion criteria: 1.Age 2.Pregnancy 3.Hemodynamic instability and/or current ICU admission. 4.Diffuse alveolar haemorrhage. 5.Advanced renal disease –defined as eGFR 6.Incomplete treatment records. 7.Concurrent microbiologically documented infection. 8.Any patient deemed to have a immediate increased risk of mortality as decided by the treating physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Achievement of SLEDAI-2K Responder Index-50 (SRI-50) improvement definition in the relevant parameters of SLEDAI-2K score between the two groups . Timepoint: day 15 30 & 60 post intervention | — |
Secondary
| Measure | Time frame |
|---|---|
| SLEDAI-2KG ScoreTimepoint: day 15 30 & 60 | — |
Countries
India
Contacts
Public ContactAnirudh Maslekar
St Johns Medical College
Outcome results
None listed